Sevda Sağ
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sevda Sağ has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yavuz Dodurga
Department of Medical Biology, Pamukkale University, Denizli, Turkey
4 shared publications - Ekrem Darendelioglu
Bingöl University
3 shared publications - İbRahim Bayav
Department of Medical Biology, Faculty of Medicine, Pamukkale University, Denizli, Türkiye
3 shared publications - Adnan Ayna
Department of Chemistry, Faculty of Science and Literature Bingol University Bingol Türkiye
2 shared publications - Levent Elmas
Department of Medical Biology, Faculty of Medicine, İzmir Bakırçay University, İzmir, Türkiye
2 shared publications - Mücahit Seçme
Department of Medical Biology, Faculty of Medicine, Ordu University, Ordu, Türkiye
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Bingol Universitesi in Türk Doğa ve Fen Dergisi
- Vol. 15 (3) , 25-33
Newly Synthesized Imidazoline Compound Regulates Apoptosis and Toll-Like Receptor Signaling in Lung Adenocarcinoma and Normal Epithelial Cells
Imidazoline is a heterocyclic compound with biological activity in regulating apoptosis, inflammation, and immune signaling. Lung cancer is a leading cause of cancer-related death, emphasizing the need for new therapies. This study examined the effects of imidazoline on apoptosis and Toll-like receptor (TLR) expression in A549 lung adenocarcinoma cells and Beas-2B normal bronchial epithelial cells. The chemical structure of the synthesized imidazoline was confirmed by FT-IR spectroscopy. Cells were treated with imidazoline, and expression of apoptotic markers (BAX, BCL-2) and TLR1-10 genes was analyzed. In A549 cells, imidazoline increased BAX and decreased BCL-2, indicating activation of intrinsic apoptosis and cell cycle arrest. Beas-2B cells showed the opposite pattern, suggesting selective toxicity toward cancer cells. Imidazoline also modulated several TLRs in both cell lines, highlighting potential immunoregulatory effects. These findings demonstrate that imidazoline promotes apoptosis and alters immune-related signaling in lung cancer cells without harming normal epithelial cells. This study is the first to report imidazoline’s impact on TLR expression in lung cancer, supporting its potential as a dual anticancer agent targeting both cell death and immune pathways.
- 30 September 2026
- Published by Bingol Universitesi in Türk Doğa ve Fen Dergisi
- Vol. 15 (3) , 25-33
Open AccessNewly Synthesized Imidazoline Compound Regulates Apoptosis and Toll-Like Receptor Signaling in Lung Adenocarcinoma and Normal Epithelial Cells
Imidazoline is a heterocyclic compound with biological activity in regulating apoptosis, inflammation, and immune signaling. Lung cancer is a leading cause of cancer-related death, emphasizing the need for new therapies. This study examined the effects of imidazoline on apoptosis and Toll-like receptor (TLR) expression in A549 lung adenocarcinoma cells and Beas-2B normal bronchial epithelial cells. The chemical structure of the synthesized imidazoline was confirmed by FT-IR spectroscopy. Cells were treated with imidazoline, and expression of apoptotic markers (BAX, BCL-2) and TLR1-10 genes was analyzed. In A549 cells, imidazoline increased BAX and decreased BCL-2, indicating activation of intrinsic apoptosis and cell cycle arrest. Beas-2B cells showed the opposite pattern, suggesting selective toxicity toward cancer cells. Imidazoline also modulated several TLRs in both cell lines, highlighting potential immunoregulatory effects. These findings demonstrate that imidazoline promotes apoptosis and alters immune-related signaling in lung cancer cells without harming normal epithelial cells. This study is the first to report imidazoline’s impact on TLR expression in lung cancer, supporting its potential as a dual anticancer agent targeting both cell death and immune pathways.
- 2 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (11) , 2945-2953
Palbociclib Induces Apoptosis and Modulates Toll-Like Receptor Expression in Lung Adenocarcinoma and Epithelial Cells
- 2 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (11) , 2945-2953
Palbociclib Induces Apoptosis and Modulates Toll-Like Receptor Expression in Lung Adenocarcinoma and Epithelial Cells
- Open Access
- 27 February 2025
- Published by Journal of Cellular Neuroscience and Oxidative Stress in Journal of Cellular Neuroscience and Oxidative Stress
- Vol. 17 (1) , 1237-1244
Chrysin protects neuronal cells against carboplatin exposure-induced apoptosis and oxidative damage
Chemotherapy drugs such as carboplatin are commonly used to treat various cancers, including testicular, lung, and ovarian cancer. Although carboplatin primarily targets cancer cells, it can also damage healthy cells, including neurons, leading to potential adverse effects. Notably, some side effects of carboplatin therapy are associated with nerve cells and the nervous system. The aim of our study was to investigate the potential protective effects of chrysin (Chr) against carboplatin-induced toxicity in SH-SY5Y neuronal cells. In this study, the ameliorative effects of Chr on carboplatin-induced cellular toxicity were evaluated through cell viability assays, lipid peroxidation (LPO) analysis to assess antioxidant capacity, TUNEL assay, immunohistochemistry (IHC) staining, and western blotting to examine anti-apoptotic activities. The results indicated that Chr mitigates carboplatin toxicity in SH-SY5Y cells by reducing LPO levels and the expression of cytochrome c (Cyt c) and Bax, while increasing the expression of the anti-apoptotic protein Bcl-2. The study also demonstrated that carboplatin caused apoptosis by causing DNA strand breaks while Chr treatment alleviated these effects. These findings suggest that the use of antioxidants, particularly Chr, may diminish the apoptotic effects of carboplatin in SH-SY5Y cells and could provide insights into potential therapeutic strategies for mitigating cell damage caused by carboplatin.
- 27 February 2025
- Published by Journal of Cellular Neuroscience and Oxidative Stress in Journal of Cellular Neuroscience and Oxidative Stress
- Vol. 17 (1) , 1237-1244
Open AccessChrysin protects neuronal cells against carboplatin exposure-induced apoptosis and oxidative damage
Chemotherapy drugs such as carboplatin are commonly used to treat various cancers, including testicular, lung, and ovarian cancer. Although carboplatin primarily targets cancer cells, it can also damage healthy cells, including neurons, leading to potential adverse effects. Notably, some side effects of carboplatin therapy are associated with nerve cells and the nervous system. The aim of our study was to investigate the potential protective effects of chrysin (Chr) against carboplatin-induced toxicity in SH-SY5Y neuronal cells. In this study, the ameliorative effects of Chr on carboplatin-induced cellular toxicity were evaluated through cell viability assays, lipid peroxidation (LPO) analysis to assess antioxidant capacity, TUNEL assay, immunohistochemistry (IHC) staining, and western blotting to examine anti-apoptotic activities. The results indicated that Chr mitigates carboplatin toxicity in SH-SY5Y cells by reducing LPO levels and the expression of cytochrome c (Cyt c) and Bax, while increasing the expression of the anti-apoptotic protein Bcl-2. The study also demonstrated that carboplatin caused apoptosis by causing DNA strand breaks while Chr treatment alleviated these effects. These findings suggest that the use of antioxidants, particularly Chr, may diminish the apoptotic effects of carboplatin in SH-SY5Y cells and could provide insights into potential therapeutic strategies for mitigating cell damage caused by carboplatin.
- 27 November 2024
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 48 (1) , 172-179
Assessment of morin hydrate as a renal protective agent in rats subjected to methotrexate-induced nephrotoxicity
Methotrexate (MTX) is a generally applied chemotherapeutic medicine in most cancers treatment. Morin hydrate, a robust antioxidant, is a secondary metabolite observed in numerous plants, along with figs, white mulberries, and others. The hypothesis of this study is that morin hydrate can effectively reduce MTX-induced kidney injury in rats by increasing antioxidant enzyme activity and inhibiting apoptotic processes. This study, 35 male Wistar albino rats were used, and five different experimental groups, each consisting of 7 rats were established. Group 1 served as the control group while Group 2 received morin exclusively via oral administration (at a dose of 100 mg/kg). Group 3, however, was administered MTX exclusively (at a dose of 20 mg/kg). Group 4 received a combination of MTX (20 mg/kg) and morin (50 mg/kg), and Group 5 received a combination of MTX (20 mg/kg) and morin (100 mg/kg). The MTX group showed a significant increase in kidney biomarkers, including serum urea, creatinine, and the lipid peroxidation biomarker MDA, compared to the control group, along with a notable decrease in antioxidant enzyme activity (SOD, CAT, GPx) and GSH levels. Furthermore, MTX notably decreased the expression of procas-3, Bcl-2, procas-9, and procas-8 while concurrently increasing the expression of apoptotic genes such as CYT-C and Bax. Co-administration of morin hydrate with MTX at doses of 50 and 100 mg/kg effectively managed oxidative damage levels and apoptotic markers, demonstrating antioxidant and anti-apoptotic properties. Notably, the 100 mg/kg dose provided more robust protection than the 50 mg/kg dose, indicating a dose-dependent efficacy. This investigation thus supports the conclusion that morin hydrate, at both dosage levels, effectively mitigates MTX-induced renal damage.
- 27 November 2024
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 48 (1) , 172-179
Assessment of morin hydrate as a renal protective agent in rats subjected to methotrexate-induced nephrotoxicity
Methotrexate (MTX) is a generally applied chemotherapeutic medicine in most cancers treatment. Morin hydrate, a robust antioxidant, is a secondary metabolite observed in numerous plants, along with figs, white mulberries, and others. The hypothesis of this study is that morin hydrate can effectively reduce MTX-induced kidney injury in rats by increasing antioxidant enzyme activity and inhibiting apoptotic processes. This study, 35 male Wistar albino rats were used, and five different experimental groups, each consisting of 7 rats were established. Group 1 served as the control group while Group 2 received morin exclusively via oral administration (at a dose of 100 mg/kg). Group 3, however, was administered MTX exclusively (at a dose of 20 mg/kg). Group 4 received a combination of MTX (20 mg/kg) and morin (50 mg/kg), and Group 5 received a combination of MTX (20 mg/kg) and morin (100 mg/kg). The MTX group showed a significant increase in kidney biomarkers, including serum urea, creatinine, and the lipid peroxidation biomarker MDA, compared to the control group, along with a notable decrease in antioxidant enzyme activity (SOD, CAT, GPx) and GSH levels. Furthermore, MTX notably decreased the expression of procas-3, Bcl-2, procas-9, and procas-8 while concurrently increasing the expression of apoptotic genes such as CYT-C and Bax. Co-administration of morin hydrate with MTX at doses of 50 and 100 mg/kg effectively managed oxidative damage levels and apoptotic markers, demonstrating antioxidant and anti-apoptotic properties. Notably, the 100 mg/kg dose provided more robust protection than the 50 mg/kg dose, indicating a dose-dependent efficacy. This investigation thus supports the conclusion that morin hydrate, at both dosage levels, effectively mitigates MTX-induced renal damage.
- Open Access
- 16 October 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Cisplatin Impact on Kasumi-1 Leukemia: Gene Expression and DNA Damage
Purpose: Leukemia is a type of cancer caused by the uncontrolled proliferation of blood cells. The purpose of this study was to investigate the effects of cisplatin (CIS), a chemotherapeutic agent used in the treatment of leukemia, on the Kasumi-1 leukemia cell line. Materials and methods: The study measured the effect of CIS on Kasumi-1 cells by calculating IC50 values for cell viability. The mRNA expression levels of apoptosis and cell cycle-related genes were then assessed using Real-Time PCR. In addition, the effects of CIS on DNA damage were investigated using the comet assay. Results: Significant changes in apoptosis and cell cycle-related genes were observed in CIS-treated groups. These included alterations in the mRNA levels of p53, BCL-2, CHECK 1, CDC25C, CDK 6, URG4/URGCP, GADD45A, CCND1, GADD45G, and ATM genes. Comet analysis confirmed CIS's effects on DNA damage. Conclusion: This study aimed to better understand how CIS affects genetic mechanisms in leukemia cells and provide new insights into leukemia treatment. The findings will help us better understand the role of CIS in leukemia treatment and will serve as a valuable reference for future research.
- 16 October 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessCisplatin Impact on Kasumi-1 Leukemia: Gene Expression and DNA Damage
Purpose: Leukemia is a type of cancer caused by the uncontrolled proliferation of blood cells. The purpose of this study was to investigate the effects of cisplatin (CIS), a chemotherapeutic agent used in the treatment of leukemia, on the Kasumi-1 leukemia cell line. Materials and methods: The study measured the effect of CIS on Kasumi-1 cells by calculating IC50 values for cell viability. The mRNA expression levels of apoptosis and cell cycle-related genes were then assessed using Real-Time PCR. In addition, the effects of CIS on DNA damage were investigated using the comet assay. Results: Significant changes in apoptosis and cell cycle-related genes were observed in CIS-treated groups. These included alterations in the mRNA levels of p53, BCL-2, CHECK 1, CDC25C, CDK 6, URG4/URGCP, GADD45A, CCND1, GADD45G, and ATM genes. Comet analysis confirmed CIS's effects on DNA damage. Conclusion: This study aimed to better understand how CIS affects genetic mechanisms in leukemia cells and provide new insights into leukemia treatment. The findings will help us better understand the role of CIS in leukemia treatment and will serve as a valuable reference for future research.
- Open Access
- 26 September 2024
- Published by Bingol Universitesi in Türk Doğa ve Fen Dergisi
- Vol. 13 (3) , 92-98
Green Synthesis of Apricot Kernel Silver Nanoparticles and Their Biological Activity
Silver nanoparticles (AgNPs) have been shown to have high conductivity, chemical stability, catalytic and antibacterial activities, as well as cytotoxicity on various cancer cells. Many biological resources, including plants, fungi, and bacteria have been utilised for the synthesis of silver, gold and other nanoparticles. The aim of this study was to synthesise environmentally friendly and cost-effective AgNPs from apricot kernel and investigate their antimicrobial activities and cytotoxicity. The synthesized AgNPs were characterized by UV-vis, X-ray diffraction (XRD), Scanning Electron Microscopy (SEM) and FTIR. UV–vis spectra revealed the surface plasmon resonance peak at 420 nm confirming the formation of apricot kernel silver nanoparticles. FTIR spectra further demonstrated the involvement of biological compounds in synthesis of AgNPs. Synthesized AgNPs was also found to inhibit the growth of gram negative and gram positive bacteria such as Enterobacter aerogenes ccm 2531, Bacillus subtilis IM 622, Staphylococcus Aureus 6538 p., Staphylococcus Aureus ATCC 29213 and Listeria monocytogenes NCTL 5348 on solid nutrient medium. Importantly, AgNPs were also found to decrease the cell viability of SHSY5Y cell lines in vitro suggesting it could be used as a controlling agent of human neuroblastoma cancer. Based on the findings, it could be concluded that environmentally friendly synthesized AgNPs shows multifunctional properties and could be used against cancer and other infectious diseases.
- 26 September 2024
- Published by Bingol Universitesi in Türk Doğa ve Fen Dergisi
- Vol. 13 (3) , 92-98
Open AccessGreen Synthesis of Apricot Kernel Silver Nanoparticles and Their Biological Activity
Silver nanoparticles (AgNPs) have been shown to have high conductivity, chemical stability, catalytic and antibacterial activities, as well as cytotoxicity on various cancer cells. Many biological resources, including plants, fungi, and bacteria have been utilised for the synthesis of silver, gold and other nanoparticles. The aim of this study was to synthesise environmentally friendly and cost-effective AgNPs from apricot kernel and investigate their antimicrobial activities and cytotoxicity. The synthesized AgNPs were characterized by UV-vis, X-ray diffraction (XRD), Scanning Electron Microscopy (SEM) and FTIR. UV–vis spectra revealed the surface plasmon resonance peak at 420 nm confirming the formation of apricot kernel silver nanoparticles. FTIR spectra further demonstrated the involvement of biological compounds in synthesis of AgNPs. Synthesized AgNPs was also found to inhibit the growth of gram negative and gram positive bacteria such as Enterobacter aerogenes ccm 2531, Bacillus subtilis IM 622, Staphylococcus Aureus 6538 p., Staphylococcus Aureus ATCC 29213 and Listeria monocytogenes NCTL 5348 on solid nutrient medium. Importantly, AgNPs were also found to decrease the cell viability of SHSY5Y cell lines in vitro suggesting it could be used as a controlling agent of human neuroblastoma cancer. Based on the findings, it could be concluded that environmentally friendly synthesized AgNPs shows multifunctional properties and could be used against cancer and other infectious diseases.
- Open Access
- 24 May 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells
Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.
- 24 May 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessInvestigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells
Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.